Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders

• Publication date: April 2012

Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders Summary GlobalData’s report, “Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders” takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle cell anemia. An international team of researchers led by scientists at Weill-Cornell Medical College in New York City have designe...

Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders

Summary

GlobalData’s report, “Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders” takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle cell anemia. An international team of researchers led by scientists at Weill-Cornell Medical College in New York City have designed a novel gene therapy strategy with potentially curative implications for patients with beta-thalassemia and sickle cell anemia. This development represents an important advance in addressing significant unmet market needs regarding the future development of therapeutic products for these two serious red blood cell disorders.

Scope

- Introduction and detail on two red blood cell disorders – sickle cell anemia and beta-thalassemia
- Current gene therapy initiatives for beta-thalassemia and sickle cell anemia
- Challenges to Gene Therapy
- Market Implications

Reasons to buy

- Understand the effectiveness of gene therapy in the treatment of red blood cell disorders
- Get the most up to date gene therapy-based research being carried out for sickle cell anemia and beta-thalassemia

Blood Supply, Tissue Banking And Transplantation Industry in the United States

1 Table of Contents
1 Table of Contents 1
2 Summary 1
3 Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders 1
3.1 Characteristics of Beta-Thalassemia and Sickle Cell Anemia 1
3.2 Novel Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia 2
3.3 Overcoming Barriers to Gene Therapy 2
3.4 Market Implications 2
4 Appendix 3
4.1 Methodology 3
4.1.1 Coverage 3
4.1.2 Secondary Research 3
4.1.3 Primary Research 3
4.1.4 Expert Panel Validation 4
4.2 Contact Us 4
4.3 Disclaimer 4